Selinexor Approved for R/R Diffuse Large B-Cell Lymphoma

Accelerated approval was granted to selinexor (Xpovio®, Karyopharm Therapeutics) to treat adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including those with DLBCL resulting from follicular lymphoma, after receiving at least two prior lines of systemic therapy. Selinexor had previously been approved in combination with dexamethasone for adult patients with R/R multiple myeloma who were previously treated with at least four therapies and whose disease is refr...
Continue reading

Polatuzumab Vedotin Approved in Relapsed/Refractory DLBCL

The FDA has now granted accelerated approval to polatuzumab vedotin (Polivy®, Genentech, Inc.) in combination with bendamustine and a rituximab product for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, following two or more prior lines of therapy. Estimates of five-year survival for DLBCL have been reported at 62.0% in the United States and 55.4% in Europe. Over 50% of patients with advanced-stage, previously untreated DLBCL experience complet...
Continue reading

B-Cell Malignancies: Treatment Advances in CAR T-Cell Therapy With Stephanie Jackson, MSN, RN, AOCNS®, BMTCN®

Outcomes have improved in recent years for patients with B-cell malignancies such as diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia (ALL), but many patients continue to develop relapsed or refractory disease. In this interview with i3 Health, Stephanie Jackson, MSN, RN, AOCNS®, BMTCN®, Oncology Clinical Nurse Specialist at the Ronald Reagan UCLA Medical Center, discusses advances in chimeric antigen receptor (CAR) T-cell therapy, which has been shown to produce significant...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.